Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
What To Know About Buying Penny Stocks on April 19th With another day of buying penny stocks here, there is a lot for investors to know. During early morning trading, we saw gainers like Sharps Technology Inc. ( NASDAQ: STSS ) and Navidea Biopharmaceuticals Inc. ( NYSE: NAVB ) g...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Aytu BioPharma's (NASDAQ:AYTU) AR101 to treat patients with Vascular Ehlers-Danlos Syndrome (VEDS). The company said it will evaluate AR101 (enzastaurin) in a trial called PREVEnt, which is expected to enr...
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AR101 (enzastaurin),...
Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) traded at a new 52-week high today of $13.07. So far today approximately 383.9 million shares have been exchanged, as compared to an average 30-day volume of 175,000 shares. Aytu BioPharma Inc. share prices have moved between a 52-week high of ...
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT® (methylphenidate) extended-release...
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management will participate in a panel discussion titled, "Managing Clinical Trials for Rare Diseases ...
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu BioPharma, wi...
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten offering of 3,030,000 shares of its common stock, pre-f...
Aytu BioPharma (NASDAQ:AYTU) announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3.03M shares of its common stock, pre-funded warrants to purchase up to 3.3M shares of its common stock, and common warrants to purchase up to 6.67M shares of i...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...